>> How About Genr and Alcon Partnering in AMD? <<
lois: Alcon would make a capable partner in marketing and regulatory affairs (i.e. getting the drug through the FDA). Moreover, Squalamine and Alcon’s Retaane might complement one another.
However, I question whether Alcon is willing to open the corporate wallet wide enough to pay GENR what the Squalamine program is worth.
Alcon might still be gun-shy after grossly overpaying for Summit Technologies, a laser-vision equipment maker, in mid-2000. Alcon’s parent company, Nestle of Switzerland, was not too happy about the way the Summit deal turned out, and made it known that they would not be inclined toward generosity the next time around.
Bottom line: Alcon is a possible partner for Squalamine, but it is probably not among the top candidates.
Market Data 
Markets 
AI
